The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.

Journal article

DNA damaging agents such as radiotherapy and gemcitabine are frequently used for the treatment of pancreatic cancer. However, these treatments typically provide only modest benefit. Improving the low survival rate for pancreatic cancer patients therefore remains a major challenge in oncology. Inhibition of the key DNA damage response kinase ATR has been suggested as an attractive approach for sensitization of tumor cells to DNA damaging agents, but specific ATR inhibitors have remained elusiv...

Expand abstract

Authors: Prevo, R; Fokas, E; Reaper, P; Charlton, P; Pollard, JR

• Publication status: Published
• Journal: Cancer biology and therapy
• Volume: 13
• Issue: 11
• Pages: 1072-1081
• Publication date: 2012-09-01
• DOI: 10.4161/cbt.21093
• EISSN: 1555-8576
• ISSN: 1538-4047
• Language: English
• Keywords: Pyrazines; Signal Transduction; Antineoplastic Combined Chemotherapy Protocols; Protein-Serine-Threonine Kinases; Humans; Combined Modality Therapy; Cell Line, Tumor; DNA Damage; DNA Repair; Cell Hypoxia; Phosphorylation; Radiation-Sensitizing Agents; Cell Cycle Proteins; Ataxia Telangiectasia Mutated Proteins; Sulfones; Pancreatic Neoplasms; Cell Cycle Checkpoints; Deoxycytidine